Takashi Motohashi

5PUBLICATIONS
55CO-AUTHORS
Predictive and prognostic markersEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 05, 2026
Clinicopathologic features and outcomes of patients with microsatellite instability-high endometrial cancer treated with pembrolizumab in Japan: the KCOG-G1902S/1903S study.

|Nov 17, 2025
Prognostic factors for malignant tumors arising from mature cystic teratomas: a study involving the Kansai Clinical Oncology Group (KCOG-G1305s study).

Fuminori Ito, Mototsugu Shimokawa, Atsushi Sugiura

|Jul 19, 2024
Niraparib as maintenance therapy in Japan: a retrospective observational study using a Japanese claims database.

Takashi Motohashi, Muneaki Shimada, Hideki Tokunaga

|Nov 13, 2020
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.

Takashi Motohashi, Akira Yabuno, Hiroshi Michimae

|Oct 03, 2019
Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan.

Harunobu Matsumoto, Mototsugu Shimokawa, Kaei Nasu

Pageof 1

Frequent Collaborators

2 joint publications

Mototsugu Shimokawa

2 joint publications

Tsutomu Tabata

2 joint publications

Kentaro Kai

2 joint publications

Hiroaki Nagano